What happens when human health, animal health, and entrepreneurial drug development intersect?

In this episode of Fractals: Life Science Conversations, Bracken CEO Colin Miller is joined by Senior Partners Graham Lumsden, BVM&S, Dip.M., MRCVS, and Jonathan Larkin, PhD, to discuss osteoarthritis innovation, One Medicine, and the collaborative pathways that can move novel therapies forward.

• Why osteoarthritis remains a major unmet need in both human and animal health
• How disease-modifying approaches could shift treatment beyond pain management
• The promise of bispecific antibody development in addressing both pain and cartilage degeneration
• How animal health studies can inform human development programs (and vice versa)
• Why human expertise, networks, and scientific judgment remain essential in the age of AI